关注
Martin Schönlein
Martin Schönlein
Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
在 uke.de 的电子邮件经过验证
标题
引用次数
引用次数
年份
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
L Pagano, J Salmanton-García, F Marchesi, A Busca, P Corradini, ...
Journal of hematology & oncology 14 (1), 168, 2021
2722021
Virus-induced senescence is a driver and therapeutic target in COVID-19
S Lee, Y Yu, J Trimpert, F Benthani, M Mairhofer, P Richter-Pechanska, ...
Nature 599 (7884), 283-289, 2021
2542021
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
J Tintelnot, Y Xu, TR Lesker, M Schönlein, L Konczalla, AD Giannou, ...
Nature 615 (7950), 168-174, 2023
1652023
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study
A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ...
Hepatology 76 (4), 1000-1012, 2022
1622022
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
L Pagano, J Salmanton-García, F Marchesi, O Blennow, ...
Blood, The Journal of the American Society of Hematology 140 (26), 2773-2787, 2022
712022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ...
European Journal of Cancer 175, 204-213, 2022
632022
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report
O Blennow, J Salmanton‐García, P Nowak, F Itri, J Van Doesum, ...
American journal of hematology 97 (8), E312-E317, 2022
572022
CD20-targeting immunotherapy promotes cellular senescence in B-cell lymphoma
JHM Däbritz, Y Yu, M Milanovic, M Schönlein, MT Rosenfeldt, JR Dörr, ...
Molecular cancer therapeutics 15 (5), 1074-1081, 2016
402016
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
YL Wu, CAM Fulgenzi, A D’Alessio, J Cheon, N Nishida, A Saeed, ...
Cancers 14 (23), 5834, 2022
372022
Post-vaccination anti-SARS-CoV-2-antibody response in patients with multiple myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment
S Ghandili, M Schönlein, M Lütgehetmann, J Schulze zur Wiesch, ...
Cancers 13 (15), 3800, 2021
352021
Improved clinical outcome of COVID‐19 in hematologic malignancy patients receiving a fourth dose of anti‐SARS‐CoV‐2 vaccine: an EPICOVIDEHA report
J Salmanton‐García, F Marchesi, A Glenthøj, YM Bilgin, J Van Praet, ...
Hemasphere 6 (11), e789, 2022
282022
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
F Marchesi, J Salmanton-García, Z Emarah, K Piukovics, M Nucci, ...
Haematologica 108 (1), 22, 2023
272023
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
A Busca, J Salmanton-García, F Marchesi, F Farina, GC Seval, ...
Frontiers in immunology 14, 1125030, 2023
212023
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
J Salmanton-García, F Marchesi, MG da Silva, F Farina, J Dávila-Valls, ...
EClinicalMedicine 58, 2023
192023
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
M Vithayathil, A D'Alessio, CAM Fulgenzi, N Nishida, M Schönlein, ...
Liver International 42 (11), 2538-2547, 2022
192022
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
JA van Doesum, J Salmanton-García, F Marchesi, R Di Blasi, ...
Blood Advances 7 (11), 2645-2655, 2023
172023
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
F Marchesi, J Salmanton-García, C Buquicchio, F Itri, C Besson, ...
Journal of Hematology & Oncology 16 (1), 32, 2023
162023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
M Vithayathil, A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, ...
Hepatology international 17 (4), 904-914, 2023
142023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
C Celsa, G Cabibbo, CAM Fulgenzi, B Scheiner, A D’Alessio, GF Manfredi, ...
Journal of hepatology 80 (3), 431-442, 2024
122024
Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
C Nitschke, B Markmann, P Walter, A Badbaran, M Tölle, J Kropidlowski, ...
Clinical chemistry 69 (3), 295-307, 2023
122023
系统目前无法执行此操作,请稍后再试。
文章 1–20